Catalyst Pharmaceuticals, Inc. (CPRX)

15.20 +0.15 (+1.00%) 收市：04:00PM EDT

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200
https://www.catalystpharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 167

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Richard John Daly M.B.A.	President, CEO & Director	68.12k	無	1961
Dr. Steven R. Miller Ph.D.	Executive VP, COO & Chief Scientific Officer	884.7k	無	1962
Dr. Gary Ingenito M.D., Ph.D.	Chief Medical & Regulatory Officer	811.39k	無	1956
Mr. Jeffrey Del Carmen	Executive VP & Chief Commercial Officer	799.82k	無	1971
Mr. Michael W. Kalb CPA	Executive VP, Treasurer & CFO	無	無	1971
Ms. Mary Coleman	VP & Head of Investor Relations	無	無	無
Mr. Brian Elsbernd J.D.	Chief Compliance Officer & Chief Legal Officer	311.42k	無	1964
Mr. Pete Curry Sr.	Vice President of Sales	無	無	無
Dr. Stanley Iyadurai M.D., Ph.D.	Senior Vice President of Medical Affairs & Drug Discovery	無	無	無
Dr. Preethi Sundaram Ph.D.	Chief Strategy Officer	511.25k	無	1976

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

公司管治

截至 2024年4月29日 止，Catalyst Pharmaceuticals, Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：9；董事會：6；股東權利：3；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。